Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from AFC-HD AMS Life Science Co., Ltd. ( (JP:2927) ).
AFC-HD AMS Life Science Co., Ltd. reported solid year-on-year growth for the first quarter of the fiscal year ending August 2026, with net sales rising 4.4% to ¥8,547 million and operating profit increasing 18.6% to ¥771 million. Ordinary profit grew 5.0% to ¥739 million, while profit attributable to owners of parent climbed 13.6% to ¥522 million, reflecting improved profitability following strong gains in the prior year. Comprehensive income rose 17.0% to ¥538 million, and basic earnings per share increased to ¥36.70 from ¥32.70, underscoring enhanced returns to shareholders. The company’s financial position also strengthened modestly, with total assets edging up to ¥49,148 million, net assets increasing to ¥15,680 million, and the capital adequacy ratio improving to 31.7%, indicating a gradually more robust balance sheet that may support future strategic investments and shareholder value.
The most recent analyst rating on (JP:2927) stock is a Hold with a Yen923.00 price target. To see the full list of analyst forecasts on AFC-HD AMS Life Science Co., Ltd. stock, see the JP:2927 Stock Forecast page.
More about AFC-HD AMS Life Science Co., Ltd.
AFC-HD AMS Life Science Co., Ltd. is a Japan-listed general business company on the Tokyo Stock Exchange Standard market, operating in the life science sector. It provides products and services related to health and nutrition, targeting consumers and business partners in the broader life science and wellness market.
Average Trading Volume: 32,661
Technical Sentiment Signal: Buy
Current Market Cap: Yen12.5B
For detailed information about 2927 stock, go to TipRanks’ Stock Analysis page.